Published in Medical Letter on the CDC and FDA, February 3rd, 2008
"We are pleased to submit this application to the EMEA, given the highly compelling data for Vidaza in the treatment of MDS," said Patrick J. Mahaffy, Pharmion's president and chief executive officer. "Vidaza is the only hypomethylating agent, and, in fact, the only drug to have shown an improvement in overall survival in this indication, and we believe it will become the standard of care throughout Europe for higher-risk MDS."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA